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Postoperative troponin measurement as a screening tool for adverse
cardiac events in adult patients undergoing moderate or major non-cardiac
surgery
Abstract

Elevated troponin levels within three days of surgery are strongly linked to major adverse cardiac events
(MACE). However, the value of screening with troponin measurements is controversial. The extent to which
this is done in routine practice is uncertain. We examined the medical records of all patients ≥45 years of age
undergoing moderate or major non-cardiac surgery in our tertiary referral hospital over a six-month period.
We determined how many patients had a troponin (TnT) measurement recorded in the first three days
postoperatively, how many of these were abnormal, and the occurrence of MACE within 30 days. Two
thousand and two hundred patients underwent 2,577 operations that met the study criteria. A postoperative
TnT was measured after 4.5% of operations. Thirty-eight percent of patients with a recorded TnT
measurement, and 44% of those with an abnormal measurement, experienced a MACE within 30 days. The
sensitivity of an abnormal TnT to detect MACE was 86%. The specificity was low at 32% with a false positive
rate of 56%. Patients with an abnormal TnT result had an increased risk of MACE (23%). The 'number needed
to measure' to detect one patient with MACE was 4.4. In our institution, postoperative TnT levels were rarely
measured and were used as a diagnostic rather than as a screening tool. The high false positive rate for MACE
prediction limits its potential value as a screening tool. The test could be considered useful if it leads to further
investigation, and may be best considered as one component of a multivariate approach to cardiac risk
evaluation and diagnosis.
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Postoperative troponin measurement as a screening tool for
adverse cardiac events in adult patients undergoing moderate
or major non-cardiac surgery
D. Coric*, N. A. Smith†

Summary

Elevated troponin levels within three days of surgery are strongly linked to major adverse cardiac events (MACE). However
the value of screening with troponin measurements is controversial. The extent to which this is done in routine practice is
uncertain. We examined the medical records of all patients ≥45 years of age undergoing moderate or major non-cardiac
surgery in our tertiary referral hospital over a six-month period. We determined how many patients had a troponin (TnT)
measurement recorded in the first three days postoperatively, how many of these were abnormal, and the occurrence
of MACE within 30 days. Two thousand and two hundred patients underwent 2,577 operations that met the study
criteria. A postoperative TnT was measured after 4.5% of operations. Thirty-eight percent of patients with a recorded TnT
measurement, and 44% of those with an abnormal measurement, experienced a MACE within 30 days. The sensitivity of an
abnormal TnT to detect MACE was 86%. The specificity was low at 32% with a false positive rate of 56%. Patients with an
abnormal TnT result had an increased risk of MACE (23%). The ‘number needed to measure’ to detect one patient with MACE
was 4.4. In our institution, postoperative TnT levels were rarely measured and were used as a diagnostic rather than as a
screening tool. The high false positive rate for MACE prediction limits its potential value as a screening tool. The test could be
considered useful if it leads to further investigation, and may be best considered as one component of a multivariate approach
to cardiac risk evaluation and diagnosis.
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Adverse cardiac events after non-cardiac surgery are
relatively common. One in twelve patients aged 45 and
over sustains an ischaemic heart injury after non-cardiac
surgery, and two-thirds of these events are asymptomatic1-4.
Symptomatic and asymptomatic myocardial infarctions
carry a similar risk of mortality1. Cardiac causes are
responsible for up to half of deaths occurring within 30 days
postoperatively1,2,5. They are also associated with substantially
increased rates of complications, prolonged hospitalisation
and increased costs1.
Diagnosis of postoperative myocardial ischaemia is not
straightforward and is often performed by detection of
raised serum troponin (TnT) levels2. The availability of highsensitivity fifth generation assays has further improved
the specificity and sensitivity of this test6. Elevated TnT
levels within three postoperative days are strongly linked
to short- and longer-term mortality5,7. Without monitoring
of perioperative TnT levels during the first few days after
surgery in patients with known vascular disease or risk
factors, the majority of myocardial infarctions and injuries
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will be undetected1. Early detection of myocardial ischaemia
allows for rapid management and potentially improved
postoperative outcomes1,8-10.
One previous report noted that in inpatients ≥45 years
of age having non-cardiac surgery, the number necessary
to screen to detect myocardial injury that would otherwise
be missed, is only about 15 patients2. One international
collaboration recommends routine monitoring of cardiac
biomarkers in high-risk patients after major surgery, with TnT
as the preferred marker11. Others have suggested that it is
not valuable as a screening tool12. TnT measurement is not
currently established as a standard postoperative screening
measure.
We performed a retrospective audit to explore how TnT
measurements were used in routine clinical practice in our
institution. We first determined how many patients aged ≥45
years undergoing moderate to major non-cardiac surgery
who stayed at least one postoperative night in our tertiary
referral hospital had a TnT measurement recorded in the first
three days postoperatively. We then explored the utility of
this measurement in the prediction of major adverse cardiac
events (MACE) at 30 days postoperatively.

Methods
This retrospective audit was registered as a quality
improvement project with The Wollongong Hospital Clinical
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Governance Unit (4/5/2016). We examined the electronic
medical records of all surgical patients ≥45 years of age who
spent at least one night in hospital postoperatively in a
six-month study period from April to September 2016.
Both scheduled (elective) and unscheduled (emergency)
procedures were included. The Wollongong Hospital is an
outer metropolitan tertiary referral centre with 500 beds.
Approximately 12,500 operations are performed each
year with all types of surgery excluding cardiothoracic and
complex paediatric procedures. The electronic medical
record includes complete information on most aspects of
inpatient care including pathology, radiology, consultations,
perioperative records, ward progress records and discharge
information.
Data were extracted for all study patients who had at
least one measurement of high-sensitivity TnT (hs-TnT) on
postoperative days 0 to 3. We followed local New South
Wales (NSW) pathology guidelines that defined hs-TnT
<14.0 ng/l as normal, with 14.0 ng/l and above as abnormal.
Electronic medical records (eMR) were accessed through
PowerChart® (Cerner, North Sydney, NSW) and manually
searched to obtain demographic and outcome data on each
patient. The clinical reasoning behind the ordering of any
individual TnT measurement was not recorded in the eMR, so
could not be audited.
MACE within 30 days of surgery was defined according to
previous literature to include cardiac arrest, acute coronary
syndrome (ACS), new onset heart failure or pulmonary
oedema, new arrhythmia, cerebrovascular accident (CVA),
and death due to a vascular cause5,13. All deaths due to nonvascular causes were also recorded, as were unplanned
postoperative intensive care unit (ICU) admissions. Data were
entered into Microsoft Excel (Microsoft® Office Professional
Plus 2013, Redmond, WA, USA) and analyses were computed
using IBM SPSS 24.0 (IBM, Armonk, NY, USA).
The statistical approach to determining the predictive value
of a marker depends on the purpose of the test and the
clinical context in which it is performed14. If the purpose of a
test is to screen for a disease state (MACE in this situation),
the test should have a high sensitivity so that few true cases
are missed. If the purpose is to make a diagnosis, then a test
should have a high degree of specificity, so that few patients
are misclassified as having the disease. A trade-off between
sensitivity and specificity always exists. The acceptability
of the balance between a high sensitivity and a high false
positive rate depends on the clinical context14. In our
situation, a high rate of false positives would mean that more
patients would be concerned about and investigated for
MACE than was necessary, whereas a high false negative rate
would suggest that a number of patients would suffer missed
or delayed diagnosis and intervention. It has been noted that
the best prediction model for an individual patient is likely to
involve multiple variables rather than a single test, and that

to be useful, any single test should improve the predictive
ability of established models15.

Results
A total of 6,372 operations were performed in the sixmonth study period. Of these, 2,577 operations were
performed in 2,200 patients aged ≥45 years who stayed in
hospital for at least one postoperative night. Of these, 116
patients (5.3%) had at least one TnT measurement on days
0 to 3 postoperatively. This cohort of 116 patients had a
total of 121 operations in the study period. The 116 TnT
measurements occurred after 4.5% of the 2,577 operations
(Table 1).
Eighty-seven of the initial postoperative TnT levels were
abnormal (75%), with 29 (24%) within the normal range.
In the total of 116 patients, 44 (38%) experienced a MACE
within 30 days of surgery (Table 2). Data from patients
who underwent more than one operation were analysed
in relation to the first operation. The large majority of
MACE events (38/44, 86%) occurred in the patients with an
abnormal TnT. The incidence of MACE in the abnormal TnT
group was twice that of the normal TnT group (44% versus
Table 1
Demographics of patients with troponin measurements
Overall
Age, mean (SD) 73.1 (11.1)

Abnormal TnT

Normal TnT

74.7 (11.2)

68.2 (9.5)

F 42 (48.3%)
M 45 (51.7%)

F 13 (44.8%)
M 16 (55.2%)

Gender, n (%)

F 55 (47.4%)
M 61 (52.6%)

Emerg v
elective, n (%)

Emerg 78 (64.5%) Emerg 62 (67.4%) Emerg 16 (55.2%)
Elective 43
Elective 30
Elective 13
(35.5%)
(32.6%)
(44.8%)

Procedure
type, n (%)
Vascular

19 (15.7%)

14

5

General

31 (25.6%)

27

4

HNENT

8 (6.6%)

8

0

Neurosurgery

6 (5.0%)

3

3

Orthopaedic

35 (28.9%)

24

11

Other

22 (18.2%)

16

6

TnT, troponin; Emerg, emergency operation; SD, standard deviation; HNENT,
head and neck and ear, nose, and throat surgery.
Table 2
Frequencies of abnormal troponins and major adverse cardiac events
MACE
TnT

Yes

No

Total

Abnormal

38

49

87

Normal

6

23

29

Total

44

72

116

TnT, troponin; MACE, major adverse cardiac event.
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Table 3
Analysis of troponin levels and major cardiac events
Index

Value

Interpretation

Sensitivity

0.864

86% of patients with a MACE were
correctly detected by the TnT.

Specificity

0.319

32% of patients without a MACE were
correctly labelled by the TnT.

Positive predictive
value

0.437

Of those labelled by the TnT as
“abnormal”, 44% had a MACE. 56% of
positive TnT results were false positives.

Negative
predictive value

0.793

Of those labelled by the TnT as “normal”,
79% did not have a MACE. 21% of
negative TnT results were false negatives.

Likelihood ratio+

1.269

A positive TnT result (i.e., labelled as
“abnormal”) was slightly more likely in
those who had a MACE.

Likelihood ratio-

2.343

A negative TnT result (i.e., labelled as
“normal”) was two times as likely to have
come from a person without a MACE.

Odds ratio

2.97

The odds of having a MACE were 3 times
higher with an abnormal TnT.

Risk difference

0.23

Patients with a positive TnT result had an
increased risk for MACE of 23%.

Numbers needed
to screen

4.4

4.4 patients must be labelled by the TnT
as “abnormal” to detect 1 patient with
a MACE.

TnT, troponin; MACE, major adverse cardiac event.

21%). Table 3 presents the predictive statistical analysis.
Patients with an abnormal TnT result had an increased risk
of MACE (23%) with a number needed to measure to predict
MACE of 4.4 patients.
A receiver operating characteristic analysis was performed.
This showed an area under the curve of 0.699 (95%
confidence interval, 0.597 to 0.801). The accuracy of
tests with areas under the curve between 0.50 and 0.70
is generally considered as low; between 0.70 and 0.90 as
moderate; and over 0.90 as high16.
A total of 62 MACEs were found in 44 patients, with many
Table 4
Types and frequencies of major cardiac adverse events
Event

Abnormal
TnT n (%)

Normal
TnT n (%)

Total

ACS

16 (100%)

0

16

Acute PO

8 (100%)

0

8

New CCF

1 (100%)

0

1

New arrhythmia

22 (85%)

4 (15%)

26

Cardiac arrest

5 (83%)

1 (17%)

6

CVA

4 (80%)

1 (20%)

5

Note: more than one type of MACE in an individual patient was common.
MACE, major adverse cardiac event, TnT, troponin; ACS, acute coronary
syndrome; PO, pulmonary oedema; CCF, congestive cardiac failure; CVA,
cerebrovascular accident.

individuals experiencing more than one type of MACE
(Table 4). Furthermore, 20 of the 25 (80%) unplanned
postoperative ICU admissions in the study patients were
in those with abnormal TnT levels. Eight deaths occurred
within 30 days of surgery in the study population. All deaths
occurred in patients with an abnormal TnT level, and all
occurred in patients who presented for emergency surgery.

Discussion
In a large cohort of patients aged ≥45 years having
moderate or major surgery in our institution, TnT
measurements were rarely performed. When performed,
75% of tests were abnormal. The low frequency and high
detection rates suggest that TnT measurements were being
performed more as a diagnostic than as a screening tool.
Predictive analysis suggests at best a moderate value for
abnormal TnT as a tool to predict postoperative MACE. The
test had a high sensitivity of 86% but its utility based on our
results would be limited mainly by the low specificity, with
a high false positive rate of 56% and low positive predictive
value of 44%.
The 116 patients in this study who had a TnT measured
were presumably a higher risk group than the rest of the
sample in whom measurements were not performed. We
were unable to assess the reasoning behind TnT requests but
postulate that they were at least to some degree performed
according to clinical indicators at the discretion of the
treating teams. The type of clinical findings that triggered
a TnT measurement could not be determined. Our findings
therefore represent the potential utility of TnT measurements
in a group with postoperative suspicion of myocardial
ischaemia based on other parameters. For patients without
this clinical suspicion, the incidence of postoperative
ischaemia is likely to be lower and the TnT test positive and
negative predictive values are likely to be less convincing.
The high sensitivity of the test (86%) is encouraging and
is close to that suggested for screening tools. Patients with
a high TnT had double the incidence of MACE compared to
those with a normal TnT level. Almost half of the patients
with an abnormal TnT level suffered at least one type of
MACE. Eighty percent of unplanned ICU admissions and all
deaths occurred in the abnormal TnT group of patients. This
approach to the data suggests that identifying a group of
patients at higher risk may be valuable if an abnormal TnT
level results in closer medical observation and treatment.
The optimal treatment to improve patient outcomes after
postoperative myocardial ischaemia is not yet established.
Treatment options include aspirin, beta-blockers, angiotensin
converting enzyme inhibitor drugs, statins, early reperfusion
strategies, and more comprehensive evaluation such as
angiography and echocardiography, but definitive outcome
studies are awaited2,8. Lack of established treatment
guidelines may limit the usefulness of early identification.
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In the real clinical world, aggressive treatment is unlikely
to be initiated after a single abnormal level without
other confirming factors such as serial measurements
or other abnormal test results. TnT measurement may
be best considered as one part of a multivariate risk
prediction model, rather than as a single measure with
a definitive binary outcome. Other potential benefits of
early identification of abnormal TnT levels include alerting
patients to their risk of future myocardial events, improving
hypertension control, and taking advantage of a teachable
moment to promote lifestyle changes, including smoking
cessation2.
The question of whether TnT measurements should be
performed in higher risk surgical populations as a routine
screening tool or only as a diagnostic tool has not yet
been conclusively answered. The most recent American
College of Cardiology/American Heart Association Guideline
recommends measurement of postoperative TnT levels only
in the setting of signs or symptoms suggestive of myocardial
ischaemia12. The current study suggests that clinical practice
in our institution reflects this guideline. Postoperative
screening in high-risk patients without signs or symptoms
suggestive of myocardial ischaemia is considered to have
uncertain value due to the absence of validated treatment
strategies to attenuate the risk of an abnormal TnT8.
Routine postoperative screening for directing perioperative
management is not recommended in this guideline.
Obtaining an electrocardiogram (ECG) was given the same
weighting as performing TnT measurements12.
On the other hand, abnormal postoperative TnT levels
have been found to be an independent predictive measure
for both MACE and mortality at various timepoints from 30
days to three years and in various surgical populations in an
increasing number of studies5,7,17-23. Most of these studies
report hazard ratios, odds ratios and logistic regression
analysis as their method of risk prediction. There have been
several recent reviews supporting routine TnT measurement
postoperatively and the field now contains a strong body of
evidence1,2,13. Without monitoring of perioperative TnT levels
during the first few days after surgery in patients with known
vascular disease or risk factors, the majority of myocardial
infarctions and injuries will be undetected1. A troponin
measurement, when added to other postoperative blood
tests, currently costs A$19.69 in our institution. At this cost,
with a number needed to measure of 4.4 patients, a decision
to use the test as a screening tool could well be considered
to be cost-effective and beneficial to individual patients. On
the other hand, it could lead to unnecessary concern and
unnecessary further investigations for many patients if not
interpreted correctly.
The background prevalence of MACE and the definition
of a ‘high-risk’ patient are clearly important factors in this
discussion. Some authorities consider a background incidence
of myocardial injury of 8% in patients aged over 45 having
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moderate or major surgery sufficient to consider the entirety
of this group as high-risk, particularly as this is such an
important clinical problem2. Others require the presence of
other cardiac risk factors, or signs and symptoms, to define a
high-risk group. Thirty-eight percent of our population with
a measured TnT experienced a MACE. It could be reasonably
supposed that clinical suspicion of myocardial injury selected
a higher risk cohort amongst our patient sample. As a
theoretical calculation, if our population in whom a TnT was
not measured, numbering 2,084 individuals, had experienced
a rate of MACE of the background 8% figure, then potentially
166 patients in the unmeasured group were at risk. A broader
use of TnT measurements may have detected more of these
patients at an early stage.
The decision about the manner in which to use the test
revolves around the intended purpose, the clinical context,
and the balance between false positives and negatives.
One could argue clinically that a high detection rate is the
priority, as treatment is only likely to occur after other more
confirmatory findings and because myocardial ischaemia is a
very important patient event. Our study suggests that almost
half of patients with a high postoperative TnT in a high-risk
group with clinical suspicion will have a MACE. The VISION
study reported that inclusion of the peak TnT in the first three
days postoperatively added incremental prognostic value to
predict 30-day mortality compared to models not including
TnT measurement5. The monetary cost of the test is low.
Clinical concerns including the time and cost of investigating
false positives need to be considered and balanced against
the risk of missing or delaying diagnosis and intervention.
This is a single-centre study, and although large
numbers were included, it may not be representative of
or generalisable to other institutions. The retrospective
nature means that we could not influence patient events or
outcomes in any way. Outcome timepoints of longer than
30 days may yield further information and be even more
relevant to patients. We did not collect detailed data on the
vast majority of surgical patients in this period for whom a
TnT was not measured. Therefore, we cannot comment on
the rate of MACE in the rest of the surgical population. Other
variables that could theoretically be important in predicting
outcomes include preoperative factors such as presence
of cardiovascular comorbidities and type of medications,
intraoperative factors such as duration and blood loss, and
postoperative factors such as level of care1. Our study was
not designed or able to investigate the potential impact of
such other variables, but these are important considerations
for overall risk reduction.

Conclusion
In conclusion, in this large pragmatic observational study,
we investigated the actual practice of postoperative TnT
measurement in a large tertiary referral hospital in Australia.
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We report that in our institution, this simple and inexpensive
measure is currently being used as a diagnostic rather
than as a screening tool. We confirm that in the setting of
postoperative surgical patients with a clinical suspicion of
myocardial ischaemia, TnT measurement can identify patients
at high risk of significantly poor outcomes, including death,
with a number needed to measure of 4.4. Our data suggest
that some of these patients may be missed if screening
measurements are not performed. The cost of the test is
low, and the cost of missing the diagnosis of postoperative
myocardial ischaemia is high. Predictive statistical analyses
suggest a low–moderate value of an elevated TnT to predict
MACE in this situation. It may have some utility in a highrisk population depending on the definition of high risk and
the clinical context. The test could be considered useful
as an early warning sign if it leads to further investigation
before aggressive treatment is undertaken and therefore
may be best considered as one component of a multivariate
approach to cardiac risk evaluation.
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